HSAKESO@EC2606A

NMPA Approves Kangkang Biotech's AK139 to Enter Phase II Clinical Trials for 7 Indications

Kangkang Biologics Grants JinChuan Pharmaceutical Exclusive Commercialization Rights to Enoximab

CanSino Biologics' PD-1/VEGF Bi-specific Antibody Ivolimab Receives FDA Acceptance

CanSinoBio Updates Contract Manufacturing Arrangement with CTTQ-Akeso

BofA Securities Initiates Coverage of CanSino Biologics with a Buy Rating

Summit Submits BLA for Ivonescimab to FDA

Daiwa Downgrades Kangchen Biotech's Rating to 'Hold' and Adjusts Target Price

Konka Biotech Develops and Approves Global First Tumor Immune Bispecific Antibody Camrelizumab

China's Pharmaceutical Industry Transforms into a Global Innovation Hub

Cancer Biologics Kangdein Biotech Makes Multiple Progresses in Core Product Pipeline

Akeso Announces Significant Efficacy in Phase II Study of Cadonilimab for Resectable Gastric Cancer

CanSino Biologics Announces Latest Findings of HARMONi-6 Trial at 2025 ESMO Asia Congress

CanAngen's 5 self-developed new drugs successfully enter the National Medical Insurance Catalog

CITIC Securities Issues Positive Report on CanAngela's Pipeline

Competition Between Kangkang Biotech and Ssan Pharmaceutical in PD-1/VEGF Bispecific Antibodies

Akeso Announces Significant OS Improvement in Ivonescimab Study

Kangkang Biotech's Ivonescimab Receives Breakthrough Therapy Designation for TNBC

CanSino Biologics Announces Final Overall Survival Check Results of HARMONi-A Study

HSBC Raises Target Price for Kangley Biotech to HKD 207 and Maintains Buy Rating

Jefferies Maintains Buy Rating on Konfenco Biologics

KEEN OCEAN

CCOE

MS CONCEPT

FULUM GP HLDG

SUMMI

PUTIAN COMM

SIWI SCI & TECH

REGAL PARTNERS

EPI (HOLDINGS)

ZIJING INTL FIN

520690

09926

520880

513700

513120

159316

159506

In Hong Kong on February 5, 2026, Akeso, Inc.announced that ivonescimab, a groundbreaking bispecific antibody targeting PD-1 and VEGF, has received its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE).

Unusual Whales

Bosera Hang Seng SCHK Innovative Drug Select ETF

AKESO

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Akeso's ivonescimab receives fifth Breakthrough Therapy Designation for treating advanced biliary tract cancer. #innovation #healthcare

516820

516500

159849

512010

588250

Akeso, Inc. has received its fifth Breakthrough Therapy Designation from the NMPA for ivonescimab, a bispecific antibody targeting PD-1 and VEGF, for first-line treatment of advanced biliary tract cancer. This designation follows previous recognitions for lung cancer and triple-negative breast cancer. A Phase III clinical study is underway, with promising results showing an Objective Response Rate of 63.6% and a Disease Control Rate of 100%. The BTD status is expected to expedite clinical development and regulatory review in China.

prnewswire

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

E Fund CSI 300 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

21:26 ETAkeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer

AKESO announced that it has signed an exclusive commercialization rights agreement with JUMPCAN, under which JUMPCAN is authorized to have exclusive commercialization rights for Yixinning (Inusimab Injection), which has been independently developed by the company and approved for listing in China (excluding Hong Kong, Macau, and Taiwan). In this cooperation, the company will receive a licensing fee of 80 million RMB, as well as milestone payments of up to 10 million RMB

AASTOCKS

JUMPCAN

AKESO grants commercialization rights for Yixinning, receiving a licensing fee of 80 million RMB

02233

01643

03708

01347

03986

00100

00340

08299

02668

In the past hour, the Hong Kong stock market has shown a clear divergence, with some individual stocks performing actively, particularly in the pharmaceutical and technology sectors where capital inflow has been significant. The strong rise of MODERN CHI MED and CH SUPPLY CHAIN seems to have attracted the attention of short-term funds, boosting overall market sentiment. Meanwhile, stocks like WESTCHINACEMENT and HUA HONG SEMI have experienced substantial declines, indicating a strong differentiation in market performance. Short-term enthusiasm is rapidly switching between different sectors, with increased volatility, leading to a cautious investor sentiment. The stock with the largest movement in the past hour, MODERN CHI MED, saw an increase of 15.07%, standing out in the market's strong performance, as funds appear confident in its future growth potential, driving the stock price up quickly. The heightened short-term sentiment has attracted a large number of buyers, creating a favorable trading atmosphere. Strong stocks: 1. CH SUPPLY CHAIN: up 12.68%, recent market recognition of its supply chain management capabilities has driven a strong rebound in its stock price. 2. MINIMAX-WP: up 10.47%, active participation from short-term funds has made it stand out in the market, showing strong buy signals. 3. MODERN CHI MED: significant increase, market expectations for its product line seem to be continuously rising, attracting substantial capital inflow. Stocks under pressure: 1. WESTCHINACEMENT: down 16.00%, increasing market concerns about its future profitability have led to greater selling pressure

HK Stock Movers Tracker

WESTCHINACEMENT

MODERN CHI MED

CH SUPPLY CHAIN

HUA HONG SEMI

GIGADEVICE

MINIMAX-WP

TONGGUAN GOLD

GT GOLD

PAK TAK INT'L

Hong Kong Stock Movement Update: MODERN CHI MED up 15.07%, CH SUPPLY CHAIN (New) up over 12%, WESTCHINACEMENT down 16%

Akeso, Inc.announced that its drug ivonescimab has been included in FirstWord Pharma's list "The Drugs That Will Shape 2026." This list highlights 20 key drugs expected to transform the pharmaceutical industry. Ivonescimab is notable as the only drug from a Chinese innovative pharmaceutical company. The list also features other significant therapies from major pharmaceutical companies. Akeso is committed to addressing unmet clinical needs and advancing innovative medicines globally, with a focus on autoimmune and neurological disorders.

Yinhua CSI Research Sector 100 ETF

23:51 ET
			
			
				Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"

01177

Akeso Inc. has updated its contract manufacturing arrangement with CTTQ-Akeso and others, confirming that the Supplemental Agreement will last until August 29, 2039. The agreement allows for a new contract based on necessity and market conditions. Annual procurement caps for monoclonal antibody products are set considering historical data and market demand, with pricing based on manufacturing costs plus a profit margin. This information is for informational purposes only and should not be considered financial advice.

Reuters

SINO BIOPHARM

Akeso Updates Contract Manufacturing Arrangement with Supplemental Agreement Expiry Set for 2039

01772

01787

01818

02020

09999

01109

06990

GIGADEVICE(03986) rose 6.14%, with a trading turnover 758.6 Million HKD, and a year-to-date rose 100.5%. GANFENGLITHIUM(01772) rose 5.54%, with a trading turnover 926.9 Million HKD, and a year-to-date rose 26.5%. ANTA SPORTS(02020) fell 4.18%, with a trading turnover 2.8 Billion HKD, and a year-to-date fell 1.8%. NTES-S(09999) fell 3.7%, with a trading turnover 2.0 Billion HKD, and a year-to-date fell 3.1%.

- The Hang Seng Index rose by 0.37%, with a year-to-date gain of 3.7%.  
- The Hang Seng Tech Index increased by 1.11% and has a year-to-date gain of 4.2%.  
- Notable stock movements include a 6.14% increase for Zhao Yi Innovation and a 4.18% decrease for Anta Sports, with the former seeing a 100.5% gain this year and the latter a 1.8% decline.

Top Gainers & Losers

GANFENGLITHIUM

SD GOLD

ZHAOJIN MINING

ANTA SPORTS

NTES-S

CHINA RES LAND

SKB BIO-B

Top 5 HK Stock Gainers/Losers (>100B) (1.21)

Akeso Inc. announced that the National Medical Products Administration (NMPA) in China has accepted the supplemental New Drug Application (sNDA) for gumokimab (AK111), a monoclonal antibody for treating active ankylosing spondylitis. This is the second indication for gumokimab to receive NDA review, following its acceptance for psoriasis. The NDA acceptance is based on positive results from a Phase III clinical trial showing significant improvements in symptoms and quality of life for patients with the condition.

Akeso sNDA for Gumokimab in Ankylosing Spondylitis Accepted for NMPA Review

00011

The CICC report pointed out that the Hang Seng Index Company will announce the results of its annual review on February 13, which may affect major indices such as the Hang Seng, the China Enterprises Index, and the Hang Seng Tech Index. It is expected that Zijin Mining International, Yum China, and BeiGene will meet the inclusion criteria, while Hang Seng Bank may be delisted and replaced by other companies. The report emphasizes that, despite quantitative standards, the actual results may differ from the forecasts

HANG SENG BANK

In "Big Banks," CICC predicts that Zijin Mining, BeiGene, property insurance, and Akeso may "replace" Hang Seng Bank in Standard Chartered's "blue" category

Akeso, Inc. announced a real-world study presentation at the 2026 ASCO GI Symposium, comparing cadonilimab plus chemotherapy to a PD-1 inhibitor plus chemotherapy for advanced gastric cancer treatment. Results showed significant improvements in overall survival (OS) and progression-free survival (PFS) for the cadonilimab regimen. The study addresses the unmet clinical need for PD-L1-low or negative patients, as current PD-1 therapies are limited to PD-L1-positive cases. Akeso is advancing Phase III studies for cadonilimab, with FDA approval for the COMPASSION-37 study expected by late 2025.

marketscreener

Akeso, Inc. Announces Presentation of Real-World Study At the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

In Hong Kong on January 13, 2026, Akeso, Inc.revealed findings from a real-world analysis at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The study compared the effectiveness of cadonilimab in combination with chemotherapy to that of a PD-1 inhibitor along with [include more information].

Real-world study at ASCO GI shows Cadonilimab beats PD-1 inhibitors in 1st-line PD-L1-low gastric cancer. Akeso, Inc.presents findings.

Akeso Inc. reported that cadonilimab plus chemotherapy outperformed PD-1 inhibitors in a study for first-line treatment of advanced gastric cancer with PD-L1 CPS <5. Results showed improved overall survival (14.3 months vs. 10.3 months) and progression-free survival (9.3 months vs. 5.8 months) for cadonilimab. The objective response rate was also higher (73.3% vs. 57.1%). Safety profiles were similar, with no significant difference in severe adverse events. The study will be published in the Journal of Gastrointestinal Oncology, and Akeso is advancing Phase III studies, including the COMPASSION-37 trial, approved by the FDA.

Akeso Reports Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer Study

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Tencent

TENCENT

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

REMEGEN

RemeGen

WUXI BIO

WuXi Biologics

BEONE MEDICINES

BeOne Medicines

Beigene

FI2 CSOP HSI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

HORIZONROBOT-W

ZA ONLINE

SINOHOPE TECH

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

FL2 CSOP HSI

LINEKONG

INNOVENT BIO

OKG TECH

Interactive Media and Services

CSOP HS TECH

XI2CSOPHSTECH

EAST BUY

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

Another day where biotech stocks stand out in the Hong Kong market $AKESO(09926.HK) sold too early, lacking vision.

In my Hong Kong stock watchlist, it's another day for innovative drugs. $AKESO(09926.HK) was sold too soon, missing a 40% gain.

Hong Kong stocks' innovative medicine sector surges 66%, three-pronged approach ignites the golden track

WUXI APPTEC

WuXi AppTec

3SBIO

DUALITYBIO-B

HENGRUI PHARMA

Hengrui Pharma

JOINN

Hong Kong stocks' innovative drugs surge 66%! Three major catalysts ignite the 'golden track', can we still get on board in the second half of the year?

On July 11, the three major stock indices in Hong Kong rose together. In terms of sectors, technology stocks rose collectively, and securities and brokerage stocks mostly increased.

LAOPU GOLD

POP MART

MIXUE GROUP

GUMING

AIA Group

The Hang Seng Index is approaching its highest level in nearly 3 years, with Chinese brokerage, insurance, and stablecoin concept stocks remaining hot!

HSAKESO@EC2606A(25150.HK)

Akeso's ivonescimab receives fifth Breakthrough Therapy Designation for treating advanced biliary tract cancer. #innovation #healthcare

21:26 ETAkeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer

AKESO grants commercialization rights for Yixinning, receiving a licensing fee of 80 million RMB

Hong Kong Stock Movement Update: MODERN CHI MED up 15.07%, CH SUPPLY CHAIN (New) up over 12%, WESTCHINACEMENT down 16%

23:51 ET Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"